drugset / Trial / NCT01342926
Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.
Timeline
- Start
- 2011-06-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK933776 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | GSK933776 | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | GSK933776 | Monoclonal antibody | 15 mg/kg | Intravenous |
Indications
No indication recorded.